Noxxon Pharma draws $50M for aptamer drugs
Noxxon Pharma, a Berlin-based biotech, raised 37 million euros ($50 million) to help push its first aptamer-based drug candidates for kidney and eye disease into clinical trials.
The main new investors included TVM Capital, Sofinnova Partners, and Edmond de Rothschild Investment Partners.
Aptamers are short stretches of DNA or RNA — generally known as oligonucleotides — that are designed specifically via an evolution-style process to latch onto a specific protein or other biological target. Because their drug… Continue Reading